- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01088880
Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever
April 27, 2012 updated by: Novartis Pharmaceuticals
An Open-label, Exploratory Study to Establish the Safety and Efficacy of 3 Months Treatment With Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever
Establish the safety and efficacy of 3 months treatment with canakinumab in patients with colchicine resistant Familial Mediterranean Fever.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
10
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Istanbul, Turkey
- Istanbul Medical Faculty, Dept of Rheumatology, Capa
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years to 75 years (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female patients between 12 and 75 years of age with active type 1 FMF disease (according to Tel-Hashomer criteria for diagnosis of FMF) despite colchicine therapy (1.5 to 2.0 mg/day).
- Patients who are intolerant to effective doses of colchicine (1.5 to 2 mg/day)
- Patients with demonstrated minimum 1 typical acute attack per month and genetic confirmation of diagnosis (with at least one of the known MEFV gene exon 10 mutations). Patients with manifested amyloidosis are excluded.
- Patients must have a historical data showing a frequency of at least 1 attack/month within the last 3 months before they can be enter the run-in period.
- Patients must have type 1 disease characterized by recurrent and short episodes of inflammation and serositis with an average of at least 1 documented acute FMF attack per month during the previous 6 months and lasting approximately 12 to 72 hours.
- Patients treated with IL-1 therapies must complete washout and have experienced at least 2 attacks since (e.g. Anakinra: 3 day washout; Rilonacept: 3 week washout)
- Patients treated with anti-TNF drugs must undergo appropriate washout. Prior to randomization, use of Etanercept must be discontinued for 4 weeks or use of Adalimumab or Infliximab must be discontinued for 8 weeks.
- Female subjects of childbearing potential must be using two acceptable methods of contraception
- Patients treated with Interferon therapies must complete 1 month washout period.
Exclusion Criteria:
- Patients with end-organ dysfunction due to amyloidosis (e.g. existing biopsy proven amyloidosis or proteinuria > 0.5 gram per day)
- Patients taking steroids within 1 month prior to baseline
- Presence or history of any other inflammatory rheumatic disease
- Positive PPD test (according to local guidance) where a latent or active TB infection cannot be excluded via Quantiferon (T-Spot or radiographic imaging if needed).
- Patients who are pregnant or lactating
- Presence of any active or chronic infection or any major episode of infection requiring hospitalization or treatment with i.v. antibiotics within 30 days or oral antibiotics within 14 days prior to screening
- History or a malignancy within the last 5 years, except for successfully excised squamous or basal cell carcinoma of the skin
Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Canakinumab
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To measure the effect of canakinumab on the frequency of FMF attacks defined as percentage of patients with at least 50% reduction in the attack frequency during 3 month treatment period.
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the effect of canakinumab with regard to percentage of patients with no attacks in month 3.
Time Frame: 12 weeks
|
12 weeks
|
To find the optimal dose of canakinumab for FMF in this population
Time Frame: 12 weeks
|
12 weeks
|
To assess changes in the severity (acute phase response and VAS evaluation of attack severity by patient) and duration of acute attacks during the treatment period
Time Frame: 12 weeks
|
12 weeks
|
To assess PK/PD properties of canakinumab by measuring canakinumab and IL-1beta levels before dosing
|
|
To evaluate the safety and tolerability of canakinumab by monitoring adverse events and patient discontinuations due to AE
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2010
Primary Completion (ACTUAL)
August 1, 2011
Study Completion (ACTUAL)
August 1, 2011
Study Registration Dates
First Submitted
March 16, 2010
First Submitted That Met QC Criteria
March 16, 2010
First Posted (ESTIMATE)
March 17, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
May 1, 2012
Last Update Submitted That Met QC Criteria
April 27, 2012
Last Verified
April 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CACZ885DTR01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Familial Mediterranean Fever
-
Rambam Health Care CampusWithdrawnFamilial Mediterranean Fever (FMF )
-
Novartis PharmaceuticalsCompletedColchicine Resistant/Intolerant Familial Mediterranean FeverIsrael
-
National Human Genome Research Institute (NHGRI)Merck Sharp & Dohme LLC; Duke University; University of Massachusetts, WorcesterRecruitingFever | Genetic Diseases | Familial Mediterranean Fever (FMF) | Autoinflammation | Periodic Fever | ROSAH | ALPK1United States
-
University of PalermoCompletedFamilial Mediterranean Fever (FMF) | Not-celiac Wheat Sensitivity (NCWS)Italy
-
University Hospital, MontpellierNot yet recruitingFamilial Mediterranean FeverFrance
-
Sohag UniversityNot yet recruitingFamilial Mediterranean FeverEgypt
-
Aristea Therapeutics, Inc.WithdrawnFamilial Mediterranean FeverIsrael, Turkey
-
University Hospital TuebingenCompleted
-
Sheba Medical CenterUnknownFamilial Mediterranean FeverIsrael
-
Sheba Medical CenterCompletedFamilial Mediterranean FeverIsrael
Clinical Trials on Canakinumab
-
Novartis PharmaceuticalsCompletedHereditary Periodic Fevers | Systemic Juvenile Idiopathic ArthritisFrance
-
Novartis PharmaceuticalsCompleted
-
University Hospital, Basel, SwitzerlandTerminatedAtrial FibrillationSwitzerland, Germany
-
Charite University, Berlin, GermanyNovartis PharmaceuticalsCompletedVasculitis | UrticariaGermany
-
NovartisCompletedChronic Obstructive Pulmonary DiseaseUnited States
-
Novartis PharmaceuticalsCompleted
-
Rabin Medical CenterUnknown
-
John MascarenhasRecruitingPrimary Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis | ET-MF | Post-polycythemia Vera Related Myelofibrosis | PV-MFUnited States
-
Novartis PharmaceuticalsPediatric Rheumatology International Trials OrganizationCompletedSystemic Juvenile Idiopathic ArthritisItaly, United States, Belgium, Germany, Greece, Russian Federation, Turkey, Spain, France, Israel, Canada, Hungary, Switzerland, United Kingdom, Brazil, Austria, Sweden, Netherlands, Argentina, Peru, Poland
-
Charite University, Berlin, GermanyTerminatedAdult-Onset Still´s DiseaseGermany